论文部分内容阅读
目的观察ⅢB型CP/CPPS患者服用塞来昔布前、后前列腺液(EPS)中细胞因子TNF-α、IL-1β和IL-6水平的变化及对疼痛治疗的效果。方法治疗组30例患者服用塞来昔布前及服药后2周。放免法分别测定EPS中TNF-α,IL-1β和IL-6的水平变化。应用NIH-CPSI表评估服药前,服药后患者疼痛评分的变化,观察疗效及有无药物不良反应。结果治疗前后TNF-α﹑IL-6均高于正常对照组(P<0.05),IL-1β治疗前后均未检测出;IL-6治疗后较治疗前明显升高(P<0.05);服药后,疼痛评分均较治疗前下降(P<0.05)。结论TNF-α﹑IL-6在ⅢB型CP/CPPS患者EPS中升高,两者可能在其病程中起重要作用;塞来昔布可以明显升高ⅢB型CP/CPPS患者EPS中IL-6水平;小剂量塞来昔布缓解ⅢB型CP/CPPS疼痛症状有效、安全。
Objective To observe the changes of cytokines TNF-α, IL-1β and IL-6 in pre-and post-prostatic fluid (EPS) of patients with type ⅢB CP / CPPS before and after taking celecoxib and its effect on pain management. Methods 30 patients in the treatment group before celecoxib and 2 weeks after taking the drug. The levels of TNF-α, IL-1β and IL-6 in EPS were determined by radioimmunoassay. The NIH-CPSI table was used to evaluate the change of pain score of patients before and after taking the medicine and to observe the curative effect and the adverse reactions of the medicine. Results Before and after treatment, the levels of TNF-α and IL-6 were higher than those of the normal control group (P <0.05), but not before and after the treatment of IL-1β. After treatment, pain scores decreased compared with those before treatment (P <0.05). Conclusions TNF-α and IL-6 are elevated in EPS of type Ⅲ B CP / CPPS patients, both of which may play an important role in its course of disease. Celecoxib can significantly increase the levels of IL-6 in EPS of type Ⅲ B CP / CPPS patients Level; small dose of celecoxib relieve type Ⅲ B CP / CPPS pain symptoms effective and safe.